<DOC>
	<DOCNO>NCT02151110</DOCNO>
	<brief_summary>Phase 1 single IV dose study evaluate safety tolerability MEDI4920</brief_summary>
	<brief_title>A Phase 1 , Randomized , Blinded , Placebo-controlled , Single-ascending Dose Study Evaluate Safety Tolerability MEDI4920 Healthy Adults</brief_title>
	<detailed_description />
	<criteria>Healthy determine responsible study physician base medical evaluation Body weight 40 100 kg Body mass index 19.0 30.0 kg/m2 History allergy sensitivity Shellfish protein base antigens previous immunization KLH previous splenectomy History diagnose suspect thromboembolic event coagulation disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Healthy Male</keyword>
	<keyword>Healthy Female non child bear potential</keyword>
</DOC>